Search for content, post, videos
Advertisement

New Head of Clinical Development at LIDDS

Charlotta Gauffin

Charlotta Gauffin will join the company in March 2019 and be responsible for the Phase IIb clinical study for Liproca Depot and the Phase I study to assess NanoZolid in combination with docetaxel.

Gauffin has extensive experience in clinical trials and project management from positions at Quintiles, Q-Med and Galderma. She holds a PhD in Organic Chemistry from the University of Uppsala. Charlotta will become a member of the LIDDS management team.

“I look forward to contributing to LIDDS clinical development and to join the management team. The NanoZolid technology is very exciting and creates many opportunities for both patients and the pharmaceutical industry,” says Charlotta Gauffin.

Broad experience in clinical trial management

“LIDDS is pleased to welcome Charlotta to the management team. She has a solid background and broad experience in clinical trial management which will be important for finalizing the LPC- 004 study and managing the NZ-DTX Phase I study. Charlotta will become a full-time employee and replace Carl-Gustaf Gölander who has made a significant contribution at LIDDS as Study Director and Clinical Program Leader, working part-time since 2015,” says Monica Wallter, CEO.

Charlotta Gauffin is leaving a position as Senior Clinical Project Manager at Galderma.

Advertisement